Angel Rodriguez
Medical Oncology · Austin, TXNPI 1487818811
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 186 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,546 and has fallen 98.9% since, to $28 in 2025. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.
Across 186 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$365
- E.r. Squibb & Sons, L.L.C.$339
- Amgen$338
- Johnson & Johnson$293
- AstraZeneca$218
- Genentech USA, Inc.$187
- plus $2K from 27 others
Across 3 payments — averaging $6846.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Radius Health, Inc.$16K
- AstraZeneca$4K
What the payments were for
- Food & beverage$3,26799%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 22 | $365 |
| E.r. Squibb & Sons, L.L.C. | 22 | $339 |
| Amgen | 17 | $338 |
| Johnson & Johnson | 22 | $293 |
| AstraZeneca(2 entities) | 12 | $218 |
| Genentech USA, Inc. | 11 | $187 |
| Sanofi | 9 | $181 |
| Merck | 9 | $152 |
| Seagen Inc. | 8 | $136 |
| Gilead | 1 | $105 |
| Ipsen Biopharmaceuticals, Inc | 3 | $96 |
| Pfizer | 6 | $91 |
| Astellas Pharma US Inc | 5 | $88 |
| Regeneron Healthcare Solutions, Inc. | 3 | $77 |
| Lilly USA, LLC | 6 | $76 |
| Incyte Corporation | 3 | $61 |
| Bayer | 3 | $53 |
| Eisai Inc. | 2 | $42 |
| EMD Serono, Inc. | 2 | $40 |
| Verastem, Inc. | 2 | $39 |
| Bristol Myers Squibb | 2 | $38 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| Dendreon Pharmaceuticals LLC | 1 | $32 |
| Mylan Institutional Inc. | 2 | $30 |
| AMAG Pharmaceuticals, Inc. | 2 | $30 |
| Heron Therapeutics, Inc. | 1 | $27 |
| Tersera Therapeutics LLC | 2 | $26 |
| AbbVie | 1 | $22 |
| Puma Biotechnology, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $17 |
| Taiho Oncology, Inc. | 1 | $16 |
| Foundation Medicine, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yescarta$105
How this compares
$3,303 in reported general payments places this provider in the 40th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Austin
- Sue EckhardtAustin$1.5M
- Miguel AlbinoAustin$322K
- Jason MelearAustin$229K
- Andrew BrennerAustin$125K
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Vijay GunugantiSan Antonio$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.